Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGX202 injection in advanced retinitis pigmentosa (phase I/II, dose-escalation and expansion)
CTR20263322Phase 2Active
- Sponsor
- Stargazer Pharmaceuticals
- Start
- Aug 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, double-blind trial of UGX-202 in retinitis pigmentosa (RP), sponsored by Stargazer Pharmaceuticals. Primary endpoint: Incidence of ocular and non-ocular adverse events through week 52. Started Aug 2026; status: active.
02
Drugs
UGX-202
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on CTR20263322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263322.